Industry

Trial-in-progress poster of Phase 1/2 CEDAR trial evaluating GPH101 for sickle cell disease to be presented as an encore SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today … [Read more…]

New compounds specifically inhibit NLRP3 in mouse models and human cells Series includes orally active small molecules capable of crossing the blood–brain barrier, enabling their use in treating neuroinflammation RICHMOND, Calif.–(BUSINESS WIRE)–BioAge Labs, Inc. (“BioAge”, “the Company”), a biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today … [Read more…]

REDWOOD CITY, Calif. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Kriya Therapeutics, Inc., a fully integrated gene therapy company pioneering novel technologies and therapeutics, today announced a $270 Million Series C financing. The financing was led by Patient Square Capital, with participation from Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya … [Read more…]

PhaseBio recently received formal written minutes from the FDA following its Pre-BLA Meeting held in early April and is expecting to submit its Biologics License Application (BLA) by early in the fourth quarter of 2022 The FDA indicated willingness to accept a BLA with data from 25-30 uncontrolled bleeding patients, in addition to surgical patients … [Read more…]

Held successful Type B pre-biologics license application (BLA) meeting with U.S. FDA for future submission of BLA for bentracimab BLA submission for bentracimab is planned for early in the fourth quarter of 2022 and PhaseBio is preparing for commercialization in U.S., if approved Presented positive results from Phase 2b trial for bentracimab at ACC.22 Completed … [Read more…]

— Under the expanded collaboration, Proteros will receive additional research funding, milestone payments plus royalties — MUNICH–(BUSINESS WIRE)–Proteros biostructures GmbH (“Proteros”), an expert in integrated structure-based drug discovery, announces today an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) focused on the discovery and development of novel epigenetic drugs. The new multi-year agreement builds on … [Read more…]

GARCHING, Germany & MUNICH–(BUSINESS WIRE)–ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will host a scientific symposium on precision oncology titled “Targeted Radionuclide Therapy – present and future prospects” held as an ancillary event in parallel to the 2022 ASCO® Annual Meeting. The symposium will feature key opinion … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2028” report has been added to ResearchAndMarkets.com’s offering. During the last few decades, there has been enormous development in the field of delivery systems to provide therapeutic agents or natural based active compounds to the target location for the management of several … [Read more…]

Where the balance of mind, body, and spirit is restored through the ancient and time-tested tenets of Ayurveda KERALA, India–(BUSINESS WIRE)–The newly-launched Amal Tamara in Alleppey, Kerala, is Tamara Leisure Experiences’ first foray into luxury wellness Ayurveda experiences. This 19-key property continues to hold the company’s core values of Responsible Hospitality at the root of … [Read more…]